At ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC
At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of just 8.5%—setting new records among global studies in this space.
50 Years of Hematopoietic Stem Cell Transplantation: Xiaojun Huang on China’s Transformative Journey
From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong…
Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang
We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a FLT3-inhibiting TKI, in treating relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) among predominantly Asian patients.
Transforming Cancer Care: Insights from Professor Jun Zhou
Professor Jun Zhou from Shanghai GoBroad Cancer Hospital and China Pharmaceutical University discusses the pivotal findings of the CheckMate 649 study. This landmark trial has redefined the first-line treatment for advanced gastric cancer, showcasing the power of immunotherapy combined with chemotherapy.
ADC Research Led by Sun Yat-sen University Cancer Center May Influence Future Treatment Guidelines
With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer Center. The results were published in Nature Medicine, one of the most respected medical journals worldwide, marking a new step in global recognition for domestically developed therapies.
Omission of surgery in early breast cancer: Are we ready for a paradigm shift?
In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…
Risk-based breast cancer screening: A shift toward personalized prevention
In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…
Professor Li Zhang’s Team Publishes Again in Nature Medicine
On April 10, 2025, a research team led by Professor Li Zhang and Professor Wenfeng Fang from Sun Yat-sen University Cancer Center published a significant study in the world-renowned journal…
Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance
At ESCMID Global 2025, Infectious Disease Frontier sat down with Dr. Francesco Cogliati Dezza to discuss the renewed clinical relevance of temocillin. As resistance to broad-spectrum antibiotics continues to rise,…